BC3195 for Advanced or Metastatic Cancer
This study is testing a new drug called BC3195 for people with advanced or metastatic (spread to other parts of the body) cancer. BC3195 is an antibody drug conjugate (ADC) that targets a protein called CDH3 on cancer cells. It delivers a chemotherapy drug directly to these cells. The main goals of this study are to find a safe dose of BC3195, understand how it moves through your body, and see if it can shrink tumors. You might be able to join if you are 18 or older, have advanced or metastatic solid tumors, and standard treatments haven't worked or you couldn't tolerate them. This study is currently enrolling participants.
- Study design
- This is an open-label study, meaning you and your doctors will know you are receiving BC3195. It has two parts: dose escalation to find the right dose, and dose expansion to further test that dose. The study plans to enroll 148 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be followed for safety from screening through 12 weeks after your last dose of BC3195.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Dose Limiting Toxicities (DLTs)First 21 days of treatment
- Determination of the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)Day 1 of treatment through 30 days after the last dose
- Incidence and Severity of All Adverse Events (AEs)Screening through 12 weeks after the last dose